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Abstract
Young women diagnosed with cancer today have a greater chance of long-term survival than ever before.
Successful survivorship for this group of patients includes maintaining a high quality of life after a cancer
diagnosis and treatment; however, lifesaving treatments such as chemotherapy, radiation, and surgery can
impact survivors by impairing reproductive and endocrine health. Studies demonstrate that future fertility is a
concern for many women diagnosed with cancer, but physician knowledge and attitudinal barriers can still
prevent females from receiving care. Today, fertility preservation is an option for girls and women facing a
cancer diagnosis, and emerging research is providing clinicians with an increasing number of reproductive and
hormonal management tools. Physicians can play an important role in fertility by working closely with on-
cologists, providing patients with information about fertility preservation options prior to the start of cancer
treatment, monitoring reproductive capacity after treatment, and working with cancer survivors to explore
potential avenues to parenthood.
Introduction
More than 135,000 people under the age of 45 yearsare diagnosed with cancer every year, and approxi-
mately one-half of these patients are women.1 Currently,
more than 70% of patients under the age of 45 who are di-
agnosed with cancer will survive more than 5 years after
treatment.2 Taken together, there are more than 270,000
survivors of pediatric cancer and more than one million
survivors of young adult cancer in the United States today.3
Quality-of-life issues for these survivors, such as fertility, are
gaining exposure in clinical and public realms. Many survi-
vors hope to have a biological family; in fact, prior studies
indicate that the process of surviving a cancer diagnosis may
actually increase the desire to have children.4–5 However, the
same life-saving treatments that increased the cancer survival
rate can also cause immediate or premature infertility in
cancer survivors.6–10 New technologies are emerging that
allow young patients to preserve their fertility before they
start treatment; however, discussions about the reproductive
risks posed by cancer treatment and the options available to
preserve fertility can be challenging in the period between
diagnosis and the start of cancer treatment. Physicians
treating women are in a unique position to discuss fertility
preservation and reproductive options for cancer patients and
survivors across the treatment spectrum. Recent research
indicates that many primary care physicians lack the aware-
ness and exposure to current clinical literature on the repro-
ductive impacts of cancer treatment.11 As physicians will be
caring for a growing population of young cancer survivors, it
is important that they understand the effects of specific cancer
treatments on fertility and the need for reproductive and
hormonal management after cancer treatment. In addition,
early referral to either a gynecologist or reproductive endo-
crinologist is recommended to ensure that women are coun-
seled about fertility preservation options.
The Reproductive and Hormonal Effects
of Cancer Treatment
Cancer treatments including surgery, chemotherapy, and
radiation can affect fertility by impacting several biologic
systems. The neuroendocrine axis, the immature and growing
follicles within the ovaries, and the reproductive organs
necessary for a woman to carry a pregnancy to term may all
be impacted by cancer treatment.
Because the hormones released by the reproductive axis
are also essential for overall growth and the health of other
body systems, damage to the reproductive system in prepu-
bescent girls may have long-term implications. Gonadal
damage caused by chemotherapy or radiation may result in
the omission, delayed onset, and abnormal development of
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secondary sex characteristics.12 Furthermore, central nervous
system radiation can result in either delayed or precocious
puberty. It is important for pediatricians, gynecologists, and
primary care providers to be aware of these post-treatment
developmental concerns.
Radiation therapy
Radiation therapy may impact the future reproductive
ability of cancer survivors in a number of ways depending on
the cumulative dose of radiation, location of the treatment,
and age of the patient.13 Women who receive abdominal or
directed pelvic radiation at high doses are at greater risk for
subsequent infertility. The ovarian reserve is sensitive to
pelvic radiation, which may destroy the majority of immature
ovarian follicles or significantly reduce follicle number. This
significant reduction in ovarian reserve may cause immediate
loss of fertility or early-onset infertility and menopause after
cancer treatment.14 Younger women may be less susceptible
to the reproductive impact of whole abdominal or pelvic ra-
diation and prepubescent girls have an even better chance of
achieving a healthy reproductive future after cancer treat-
ment when compared with older women.15–16 Pelvic radia-
tion can also permanently damage uterine elasticity and the
musculature and vasculature of the endometrium, which may
result in increased risk of miscarriage, mid-trimester preg-
nancy loss, preterm birth, and low birth weight regardless of
the age of exposure.17–19 To this end, a study of childhood
cancer survivors that received abdominal radiation indicated
an increased risk for miscarriage and premature delivery later
in life.20
The neuroendocrine axis is critical to regulating the men-
strual cycle and preparing the woman’s body for pregnancy.
The hypothalamus and pituitary glands are especially sensi-
tive to high levels of cranial or brain irradiation, which may
prevent regulated secretion of gonadotrophin-releasing hor-
mone (GnRH), follicle-stimulating hormone, and luteinizing
hormone, which in turn affects release of estradiol, proges-
terone, and prolactin. Spinal irradiation may also jeopardize
reproduction after cancer, as higher rates of miscarriage have
been reported after this treatment.21 Women whose cancer
treatment causes damage to both the brain and pelvic regions
are at the highest risk for reproductive loss after cancer. Thus,
options for fertility preservation should be discussed early
with patients who may receive total body irradiation. For
example, women who undergo total body irradiation prior to
hematopoietic stem cell transplantation should be informed
of their fertility preservation options as early as possible.
Chemotherapy
Certain chemotherapeutic agents may also negatively im-
pact future reproductive options for young cancer survivors.
Chemotherapeutic treatments can be gonadotoxic to pri-
mordial follicles, as they cause DNA strand breaks, induce
apoptosis, and reduce stromal function within the ovary.22
The most damaging chemotherapies include alkylating che-
motherapies, such as cyclophosphamide, busulfan, melpha-
lan procarbazine, and chemotherapeutic combinations that
include alkylating chemotherapies. As found with radiation
therapy, younger age appears to be fertoprotective for sur-
vivors, possibly due to the larger ovarian reserve present at
the time of cancer treatment.15 While reduction of the ovarian
reserve is thought to be the cause of most of the reproductive
damage from chemotherapy, there is also evidence that
chemotherapy may impact the neuroendocrine axis. After
receiving chemotherapy, many cancer survivors have growth
hormone deficiency, hypothyroidism, or pubertal abnormal-
ities.12 Thus, chemotherapy may damage fertility by affect-
ing either the nervous system or pelvic reproductive organs.
Many female survivors may have difficulty conceiving
after cancer treatment, but the infertility risks for different
age groups and cancer treatments are variable.23 The risk of
immediate and long-term amenorrhea after cancer treatment
is impacted by both the specific chemotherapeutic regimen
used and the age at which the woman was exposed.24 In
addition, women may experience transient chemotherapy-
induced amenorrhea, with menstruation resuming after ces-
sation of treatment. The type of chemotherapy, such as the
inclusion or absence of alkylating agents, has a significant
effect on menstruation recovery.25–26 In one study of breast
cancer patients who were treated with cyclophosphamide,
methotrexate, and 5-fluorouracil, no patient reported re-
sumption of menses, while other treatments (e.g., doxorubi-
cin and cyclophosphamide; doxorubicin, cyclophosphamide,
and paclitaxel) resulted in increased rates of recovery.26
Furthermore, while more than half of women with at least
6 months of amenorrhea do resume menstrual cycles within
three years, only 10% of women who experience more than
24 months of amenorrhea are likely to resume menses. In
addition, age at diagnosis is a significant predictor of amen-
orrhea. Women over the age of 40 years at the age of cancer
treatment are 25 times more likely to have 6 or more months
of amenorrhea than those treated at age 35. In contrast,
only 11% of women 20–34 years of age reported to a loss
of menstruation 6 months or more after the completion of
chemotherapy.26
Regardless of whether treatment-induced amenorrhea is
transient or not, premature menopause is a significant con-
cern for the reproductive and long-term endocrine health of
cancer survivors. Studies of childhood cancer survivors in-
dicate that premature menopause is most likely to occur in
patients exposed to pelvic radiation or alkylating agents.27
Ovarian failure in female survivors of pediatric cancer was
found to be most common in those patients who received
>10 Gy of radiation to the pelvis, alkylating agents, or pro-
carbazine.27 However, in studies where female cancer sur-
vivors received treatments without alkylating agents (e.g.,
doxorubicine, bleomycine, vinblastine, and dacarbazine;
epirubicine, bleomycin, vinblastine, and prednisone) no sig-
nificant increase in premature menopause was observed and
patients did not experience subfertility.28–31 Though the data
regarding the fertility of cancer survivors is far from com-
plete, obstetricians, gynecologists, and family physicians
may find models to predict premature menopause to be of
some use, offering both providers and patients a general risk
estimate after cancer treatment.16,32
Surgery
Surgical procedures required to treat cancer may also af-
fect the fertility of cancer survivors. For women diagnosed
with gynecologic cancer, these procedures can include re-
moval or one or both ovaries and partial or complete removal
of the fallopian tubes, uterus, vagina, or cervix. Additionally,
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procedures that affect the bladder, large intestine, and rectum
may also impair a woman’s ability to carry a pregnancy to
term. As fertility and survivorship considerations have gained
exposure in the clinical and public spheres, cancer treatments
have been identified that provide women and girls with a
greater chance at a reproductive future. Fertility-sparing
procedures—for example, radical trachelectomy for early-
stage cervical cancer—may increase the likelihood to con-
ceive and carry a pregnancy after cancer.
Fertility Preservation Prior to Cancer Treatment
Historically, women have had few options to preserve their
fertility when compared with men. In recent years, however,
a number of fertility preservation techniques have been
developed for females. Some of these methods have been
adapted from those used in the assisted reproductive tech-
nology (ART) field, and others have been developed specif-
ically to preserve the reproductive options for patients prior
to undergoing cancer treatment. Current emphasis is being
placed on the development of new fertility preservation op-
tions to provide a fertile future for all young cancer patients,
including those who cannot participate in traditional ART
treatments, such as prepubertal girls.33–34
Embryo cryopreservation
Embryo cryopreservation following in vitro fertilization
(IVF) is the most widely available and well-established fer-
tility preservation strategy today.35 According to the Society
for Assisted Reproductive Technologies, data from 2010
indicate that 38% of frozen–thawed embryo transfers resulted
in live births to women younger than 35 years (average 1.9
embryos transferred).36 Embryo cryopreservation is a com-
mon fertility preservation option for women with partners or
sperm donors who can contribute sperm for egg fertilization.
However, the additional decision making required to select
donor sperm may be an insurmountable barrier, emotionally
and logistically, for some women in the immediate period
after a cancer diagnosis. The ovarian hyperstimulation re-
quired for in vivo follicle development prior to retrieval may
require a slight delay of cancer treatment, from 2 to 4 weeks;
this delay may not be possible for women with certain can-
cers. Furthermore, ovarian stimulation can only be used in
postpubertal women. In addition, patients must to be physi-
cally evaluated and determined to be eligible to undergo
ovarian stimulation. Thus, embryo cryopreservation may not
be a suitable option for all female cancer patients. It is also
important to counsel women that pregnancy rates for women
undergoing embryo cryopreservation for fertility preserva-
tion are currently unknown.
Oocyte cryopreservation
Hormone-induced hyperstimulation can also be used in the
absence of a sperm donor to recruit follicles for immediate
oocyte cryopreservation. The large water content of mature
eggs—the largest single cell in the mammalian body—has
posed challenges to the freezing process. In the past decade,
advances in a form of the rapid-freezing called vitrification
has significantly improved mature egg cryopreservation and
thaw rates for women who wish to preserve their fertility
in the absence of donor sperm. Egg cryopreservation is an
option for postpubertal girls and women who do not have a
partner and do not wish to use donor sperm. Oocyte cryo-
preservation is considered ethically preferable for legal
minors, avoiding the need for the complex decision-making
process required to choose donor sperm for embryo bank-
ing.37 Historical success rates for egg cryopreservation had
been low; however, with the advent of new vitrification
processes, recent studies indicate that egg survival rates after
thaw can be upwards of 90%.38–39 The American Society of
Reproductive Medicine (ASRM) recently reversed older
guidelines, stating that oocyte cryopreservation should no
longer be considered experimental.40–41 With the increased
success rates and the research on egg cryopreservation that
has occurred in recent years, ASRM now identifies oocyte
cryopreservation as an established technique for fertility
preservation.42–43
Ovarian tissue cryopreservation
An investigational technique, ovarian tissue cryopreserva-
tion may provide reproductive options to additional subsets of
young cancer patients. This may be an option for females un-
able to undergo ovarian stimulation or prepubertal girls.44–45
For this to be accomplished, either an entire ovary or a por-
tion of an ovary is removed, typically laparoscopically, and
the cortex is cryopreserved. Patients need to be healthy en-
ough to undergo surgery in order to have this procedure.
According to the world literature, 37 children have been born
from ovarian tissue transplantation; however, the total num-
ber of women who have attempted autotransplantation is not
known, preventing accurate estimates for the success rate
for this technique.46–50 Despite not knowing the total number
of autotransplantations attempted, the success rate of this
method can be inferred from data collected from several
European centers that have reported the number of attempted
autotransplantations in addition to live births at their respec-
tive centers. Between these four centers, 80 women attempted
autotransplantation and the pregnancy rate was found to be
25% (20/80), with 16 women reporting a live birth.50 Hor-
monal and reproductive results from published ovarian tissue
transplantation procedures indicate that ovarian tissue may
provide hormonal and reproductive capacity for a limited
period of time.51 In addition to fertility preservation, recent
research and patient cases indicate that ovarian transplanta-
tion may also be used to restore hormonal function in women
with early onset menopause or to induce puberty in age-
appropriate cancer survivors.52–53
Ovarian tissue cryopreservation may not be an appropriate
fertility preservation option for all cancer patients. With au-
totransplantation comes a potential risk of reintroducing can-
cer cells.54–55 Though the exact risk is unknown, autopsies of
cancer patients show that cancer metastasis to the ovaries
range from 8.4% to 55% depending on the type of cancer.56 In
one study, eight patients aged within the range of 13 and 20
years old with Ewing sarcoma (EWS), which recently has been
reclassified from low to moderate risk of ovarian metastasis,
were examined.55,57 Based on pathological/molecular studies,
there was no evidence of EWS in the ovaries; however, in one
patient a reverse transcription polymerase chain reaction (RT-
PCR) showed EWS translocation despite the absence of
pathological evidence.57 Among pathologies investigated,
leukemia presents the highest risk of reintroducing malignant
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cells with autotransplantation, especially if ovarian tissue
cryopreservation was performed when that patient had ac-
tive disease. However, there is a much a lower risk of re-
introducing malignant cells if ovarian cryopreservation is
carried out when patients are in complete remission.55 Thus,
women with pelvic or hematologic cancers may not be ap-
propriate candidates for ovarian tissue transplantation. In-
stead, researchers are working to perfect techniques of
in vitro follicle growth from cryopreserved ovarian tissue.58
The ability to grow follicles and mature eggs in vitro to a
stage where they are capable of fertilization would allow
women to preserve their fertility without a delay in cancer
treatment and without the risk of reintroducing cancer cells.
Ovarian transposition/oophoropexy
A variety of other fertility preservation methods of estab-
lished and experimental natures also exist that provide op-
tions for women with specific cancers or treatment types.
Two standard fertility preservation techniques can be offered
to women who would like to protect their reproductive organs
from radiation therapy. Ovarian transposition/oophoropexy
involves surgically moving the ovaries and fallopian tubes
out of the field of radiation exposure, and radiation shielding
further blocks radiation to the reproductive organs. However,
neither of these techniques protects against the gonadotoxic
effects of chemotherapeutics.59 Furthermore, oophoropexy
does not protect the uterus from radiation-induced structural
and vascular damage that may reduce the likelihood of em-
bryo implantation and impair a woman’s ability to success-
fully carry a pregnancy to term.60 In one study 37 cases of
ovarian transposition were examined. Of this sample size, 18
pregnancies were achieved among 12 patients (32%). Five of
these pregnancies ended in miscarriage and the other 13
pregnancies produced 15 live births.61
GnRH agonist treatment
Ovarian suppression to prevent iatrogenic loss of ovarian
reserve, using a gonadotropin-releasing hormone agonist, is
another potential method of fertility preservation being ac-
tively investigated. The precise mechanism of these drugs is
unknown and the results of studies regarding the efficacy of
GnRH agonist (GnRHa) for fertility preservation purposes
are inconsistent.62–63 In a recent study that measured meno-
pausal status of cancer patients who underwent chemother-
apy with and without GnRHa, researchers found that a year
after the last cycle of chemotherapy, premature menopause
was significantly lower for women in the agonist group when
compared with the control group.64 While menstruation in
these patients is not an indicator of current fertility or reduced
ovarian reserve, it does provide evidence that GnRHa may be
a potential way to maintain long-term endocrine health after
cessation of cancer treatment.65 More recent studies in wo-
men with breast cancer suggest that treatment with GnRHa
may decrease the risk of premature ovarian failure.64,66
While GnRHa treatment has been associated with a statisti-
cally significant reduction in premature ovarian failure, ad-
ditional work using more established markers of ovarian
reserve is needed to better assess the role of GnRHa as a
method for fertility preservation.67–68 In addition, studies
comparing various GnRHa should be done. Furthermore,
accurate communication to patients about the differences
between menstruation and fertility is essential. Although
there is still controversy over GnRHa in preserving fertility as
a standalone treatment, its administration as a co-treatment to
cryopreservation of embryos, ova, and ovarian tissue may
increase the odds of fertility preservation.65
Assessing Ovarian Reserve
Before and after cancer treatment, female patients may
wish to assess their fertility status. The gynecological com-
munity and family practitioners may aid cancer survivors
during this challenging time by providing them with infor-
mation about their ovarian reserve and ability to carry a
pregnancy and reviewing reproductive options. While as-
sessing any remaining endogenous reproductive ability in
cancer survivors, clinicians should consider the patient’s age
at diagnosis and their current age, cumulative doses of che-
motherapy and radiation, types of chemotherapies used, and
the patient’s menstrual and fertility history.
Assessing endogenous reproductive potential and ovarian
reserve after cancer treatment can include a variety of mea-
surements. Follicle stimulating hormone and estradiol blood
measurements at day three of the menstrual cycle can indicate
potential issues with ovarian health or the neuroendocrine
axis. Currently, the most accurate hormonal measure of
ovarian reserve can be achieved with anti-Mu¨llerian hor-
mone (AMH) testing. AMH stays relatively stable across the
menstrual cycle compared with other hormonal measures and
is constant throughout the reproductive lifespan before de-
creasing prior to menopause. For these reasons, it has been
used as a measure of response to hormonal stimulation for
traditional infertility patients undergoing IVF.69 In conjunc-
tion with AMH testing, transvaginal ultrasounds to count
antral follicles can provide an indication of the number of
dormant and growing follicles within a woman’s ovaries. As
more women delay childbearing into their thirties, more will
face a cancer diagnosis prior to having biological children. As
such, many cancer survivors will have an interest in dis-
cussing their future reproduction with their primary care
physicians while still in some state of active cancer treatment
or during survivorship.
Timing of Pregnancy
Considerations about the safety and timing of pregnancy
after cancer should be discussed among patients, their cancer
treatment team, and their family physicians. Women who are
not interested in pregnancy should be encouraged to use
adequate contraception. Multiple retrospective cohort studies
have found no increased risk of cancer recurrence in breast
cancer survivors who become pregnant.70–71 In fact, retro-
spective studies demonstrate that breast cancer survivors who
become pregnant after diagnosis had improved survival
compared with those who do not become pregnant. 70–71 Yet,
while robust, these retrospective studies are limited by in-
herent bias issues and must be viewed accordingly. Though
questions about when to attempt pregnancy after cancer
treatment are common, limited data exists to guide the field.
One study in breast cancer survivors found a survival benefit
in women who waited 2 years or more after diagnosis to
attempt conception.71 In cases where the oncology team
suggests a 5- to 10-year wait before attempting pregnancy,
age can be an important factor. Five to ten years of the
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selective estrogen receptor modulator (SERM) treatment ta-
moxifen will impact a 25-year-old differently than a 35-year-
old. Women who are taking SERMs are able to ovulate and
thus should be on adequate contraception during treatment as
tamoxifen is a teratogen. If interested in conception during
this prescribed treatment, women should discuss how to best
incorporate pregnancy into their survivorship plan; for ex-
ample, by discontinuing treatment during a pregnancy and
then reinitiating after childbirth. Such factors should be dis-
cussed in detail before, during, and after cancer treatment.
Other Family Building Options
Though cancer treatment can significantly impact a wom-
an’s ability to conceive and carry a pregnancy to term, many
options are now available to cancer survivors. Women who
have a reduced ovarian reserve but are able to carry a child
may utilize a donor eggs fertilized with a partner’s semen or
donor sperm. Using a donated embryo may also be of interest
to some women. Alternatively, women with a healthy ovarian
reserve who are unable to successfully carry a pregnancy due
to surgical or radiation damage to the reproductive organs may
undergo hormonal stimulation and IVF with the resulting
embryos carried by a gestational surrogate. Adoption is also
an option for cancer survivors, though recent research exam-
ining policies of adoption agencies revealed isolated cases of
de facto discrimination.72 However, significant variability
exists in the attitudes of the adoption community, and survi-
vors should be encouraged to work with multiple agencies.
Conclusion
More than 40 years ago, the ‘‘war on cancer’’ was launched
with the passage of the National Cancer Act and the
strengthening of the National Cancer Institute. At that time, a
cancer diagnosis was often a death sentence. Since then,
survival rates for cancer patients have increased dramatically,
raising the importance of survivorship and overall quality-
of-life considerations for the many people who successfully
fight their disease. As 10% of all cancer patients are under the
age of 40 at diagnosis, these considerations often include the
desire to have a family after cancer and long-term endocrine
management that can affect the overall health of survivors.
Though the number of fertility preservation options for
women has increased significantly in recent years, many
young cancer patients still do not receive information
about the ability to preserve their fertility prior to cancer
treatment and reproductive counseling after treatment.73–74
The primary care community is in a unique position to provide
this information, including referrals to appropriate subspe-
cialists and care for young female cancer survivors, incorpo-
rating reproductive goals into the patient’s overall survivorship
plan. We recommend early referral to either a reproductive
endocrinology and infertility specialist or a gynecologist
comfortable with discussing fertility preservation options.
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